Loading...
Loading...
TARS| Name | Value |
|---|---|
| Revenues | 48.1M |
| Cost of Revenue | 3.2M |
| Gross Profit | 44.9M |
| Operating Expense | 70.0M |
| Operating I/L | -25.2M |
| Other Income/Expense | 1.7M |
| Interest Income | 4.1M |
| Pretax | -23.4M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -23.4M |
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of innovative therapeutic candidates for ophthalmic conditions. Its lead product candidate, TP-03, is in Phase III for treating blepharitis and meibomian gland disease caused by Demodex mites. The company is also developing TP-04 for rosacea treatment and TP-05 for Lyme prophylaxis and community malaria reduction. Additionally, Tarsus Pharmaceuticals is working on lotilaner, addressing diseases in eye care, dermatology, and other therapeutic categories in human medicine.
